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Abstract
Ependymal tumors constitute a clinicopathologically heterogeneous group of brain tumors. They
vary in regard to their age at first symptom, localization, morphology and prognosis. Genetic data
also suggests heterogeneity. We define a newly recognized subset of ependymal tumors, the trisomy
19 ependymoma. Histologically, they are compact lesions characterized by a rich branched capillary
network amongst which tumoral cells are regularly distributed. When containing clear cells they
are called clear cell ependymoma. Most trisomy 19 ependymomas are supratentorial WHO grade
III tumors of the young. Genetically, they are associated with trisomy 19, and frequently with a
deletion of 13q21.31-31.2, three copies of 11q13.3-13.4, and/or deletions on chromosome 9. These
altered chromosomal regions are indicative of genes and pathways involved in trisomy 19
ependymoma tumorigenesis. Recognition of this genetico-histological entity allows better
understanding and dissection of ependymal tumors.
Background
Ependymal tumors include a broad histological and clin-
ical spectrum of lesions presumably derived from epend-
ymal cells contributing to the lining of the cerebral
ventricles and the remnants of the central canal of the spi-
nal cord [1]. Their overall incidence is 0.23 cases per
100,000 individuals per year in the United States, with a
mean age at diagnosis of 35 years and an overall 5-year
survival of 66% [2]. Ependymal tumors represent the sev-
enth most frequent primary brain tumor in adult and the
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third in children. The last WHO classification comprises
WHO grade I myxopapillary ependymoma and sub-
ependymoma, WHO grade II ependymoma, and WHO
grade III anaplastic ependymoma [1].
In contrast to astrocytic and oligodendroglial tumors, in
which molecular alterations associated with tumorigene-
sis are relatively well established, less is known about
molecular changes in ependymal tumors. Monosomy of
chromosome 22 and gain of chromosome 7 occur more
frequently in spinal cord than in intracranial tumors [3].
In contrast, gain of chromosome 1q, and losses of chro-
mosomes 6q, 9, and 13, are more frequently observed in
the latter [3-5]. The involvement of chromosome 9 in
ependymal tumors led to study the three 9p21 located
tumor suppressor genes, CDKN2A, CDKN2B and p14ARF.
Deletions of CDKN2A were found in 25% of the investi-
gated tumors [6]. Promoter methylation of CDKN2A,
CDKN2B and p14ARF was detected in 20–30% of tumors,
with variations according to clinico-pathological charac-
teristics [7].
Here we have analyzed ependymomas which have lost at
least 9p and discovered that most of these tumors share
architectural features, reminiscent of clear cell ependy-
moma. We performed array-CGH on a series of such
tumors and observed trisomy 19 to be present in all of
them. This copy number change was associated with alter-
ations in chromosomes 9, 11 and/or 13. This data allowed
us to define a new genetico-histological ependymal tumor
entity, the trisomy 19 ependymoma. Histologically, they are
compact with a clear tumor-to-parenchyma interface, pre-
senting a branched capillary network and regularly dis-
persed tumoral cells. Clinically, most are supratentorial
WHO grade III tumors of the young. This data under-
scores the heterogeneity within ependymal tumors and
the need for further genetic dissection, a mandatory step
to establish personalized oncological practice.
Results
Chromosome 9 microsatellite analysis of the formalin-
fixed and paraffin-embedded ependymal tumor series and 
association with clinico-pathological parameters
PCR amplicons with interpretable results for chromo-
some 9 markers used were obtained for 131 of the 149
tumors (89%). Fifty-nine were located in the posterior
fossa, 27 in the supratentorial compartment, 17 in the spi-
nal cord, 26 in the conus-cauda-filum, and 2 in an
unknown localization. For 9 tumors, most of the 29 tested
microsatellites on chromosome 9 were deleted (median
89%, with a range between 78% and 100%, Figure 1: A1-
2, A4-5 and A10 and, B1-4). For an additional tumor,
deletion was restricted to the p arm (Figure 1: A6) and in
a last one, interstitial deletions of both arms were
observed (Figure 1: A9). These 11 tumors were classified
as having a deletion on chromosome 9 (8,5%). Three of
them were located in the posterior fossa (Figure 1: B1-3),
and presented classical ependymoma histology. The other
8 were located in the supratentorial compartment (Figure
1: A1-2, A4-6, A9-10 and B4). Seven of them demon-
strated a compact architecture, regularly dispersed
tumoral cells, chicken-wire vessels (Figure 1: A1-2, A4-6
and A9-10), and sometimes foci of clear cells (Figure 1:
A1, A4-5, and A9-10). This prompted us to perform
genomic profiling for tumors of such clinico-pathologic
characteristics.
Whole genome array-CGH
Two of us (MMR and CG) re-reviewed the histology of the
supra-tentorial ependymomas of the formalin-fixed and
paraffin-embedded series to identify additional tumors
with histology similar to that of the above described 7
tumors, and without chromosome 9 deletion. Five such
tumors were identified bringing the total to twelve epend-
Clinico-pathological analysis of paraffin embedded supra-ten- torial ependymal tumors, sub-ependymomas excluded, and of  posterior fossa ependymomas presenting deletions of chro- mosome 9 Figure 1
Clinico-pathological analysis of paraffin embedded supra-ten-
torial ependymal tumors, sub-ependymomas excluded, and of 
posterior fossa ependymomas presenting deletions of chro-
mosome 9. Tumors are divided in between trisomy 19 
ependymomas and ependymomas.Molecular Cancer 2007, 6:47 http://www.molecular-cancer.com/content/6/1/47
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ymomas with the histology of interest (marked A1-12,
Figure 1). As DNA extracted from archival tumors is suita-
ble for array-CGH [8-11], this technique was applied to 11
of these tumors for which enough DNA was available
(Figure 1: A1-9 and A11-12). In addition, 3 ependymo-
mas with classical histology (Figure 1: B1, B3 and B19)
were profiled. Two of them presented a monosomy 9 by
microsatellite analysis (Figure 1: B1 and B3). Results were
obtained for 79% (11/14) of tumors, 9 with the histology
of interest and 2 controls (Figure 2 and Figure 1: A1-9, B1
and B19). Genetic profiles divided them into two distinct
groups.
The first one comprised of 9 tumors: 3 were recurrent and
6 primary (Figure 2C: A1-9 and Figure 1: A1-9). They all
shared trisomy of chromosome 19 (Figure 2A, B, C),
which was non-complete in some tumors (tumor A4, lack
of telomeric q region amplification: Figure 2B, C). In this
group, altogether 118 genetic anomalies were detected
with a mean of 13 per tumor. They consisted of 74 gains
(64%) and 44 losses (36%). Deletions on chromosome 9
were observed in 7/9 tumors (Figure 2A, B, C and Figure
1), limited to 9p in one tumor (tumor A6: Figure 2B, C
and Figure 1), to interstitial deletions in another (tumor
A9: Figure 2B, C and Figure 1) and, without 9qter loss in
3 (Figure 2B: A2, A4 and A5). An equally frequent deletion
of 30 Mb was located at 13q21.31-13q31.2 (Figure 2A, B,
C). Gain of a small region located at 11q13.3-13.4 was
observed in 6 tumors (Figure 2A, B, C). Chromosome 17
telomeres were co-amplified in 5/9 tumors, and a sixth
one had an amplification restricted to 17q telomere (Fig-
ure 2B). Chromosomes 1, 7, and 20 also frequently
showed telomeric p or q amplifications (Figure 2B). Other
whole chromosomal abnormalities, though less frequent,
included monosomy 3 (1/9), trisomy 6 (1/9), trisomy 7
(2/9), trisomy 8 (2/9), monosomy 18 (1/9), trisomy 18
(1/9), trisomy 20 (1/9), and trisomy 22 (2/9) (Figure 2B).
The second group comprised of two tumors (Figure 2C:
B1 and B19) neither one of which presented the recurrent
chromosomal anomalies of the first group, with the
exception of monosomy 9 in one tumor (B1). Nine
genetic anomalies were observed per tumor consisting of
7 gains (39%) and 11 losses (61%).
Whole genome profiling of frozen ependymal tumors by 
SNP-arrays
On the series of 24 frozen ependymomas, all presenting
classical histological features of ependymoma, we
observed only one ependymoma with partial trisomy of
chromosome 19. This lesion was located at the spinal
cord. It appeared as a compact tumor of low cellularity,
devoid of mitosis, vascular proliferation and necrosis.
This tumor, like the 23 other frozen ependymomas, did
not fulfil clinico-histological aspect of the 9 ependymo-
mas with a trisomy 19. Thus, altogether, 26 controls (24
frozen ependymomas + 2 paraffin-embedded ones, B1
and B19) were analyzed, and only one showed a partial
trisomy 19 giving a p value < 0,001 (Fisher's exact test) for
the presence of trisomy 19 in our first group of tumors.
Characterization of trisomy 19 ependymoma
The tumor group defined by the presence of trisomy 19 on
array-CGH (A1-9), shared many clinico-pathological fea-
tures (Figure 1: A1-9). In 8/9 cases, localization was
supratentorial, for one it was unknown. The age at diagno-
sis ranged between 0.4 and 30 years, with a mean at 14
years and a median at 18 years (Figure 1). Histologically,
they appeared compact with a well-demarcated brain-to-
tumor border (Figure 3A). They presented a rich network
of branched capillaries, reminiscent of the one of 1p/19q-
deleted oligodendroglioma (chicken-wire vessels, Figure
3B, 4B, 4F and 4R), and tumoral cells were regularly dis-
tributed. In addition, pseudorosettes were always
detected, meanwhile sometimes rare (Figure 3C). Micro-
calcifications were frequently encountered, and regions of
classical ependymoma histology could be observed.
Tumoral cell phenotype varied between tumors and
sometimes within the same tumor (Figure 4). In 3/9
tumors, most of the cells were ovoid with a clear perinu-
clear halo (Figure 1: A1, A5 and A9, and Figure 4A and
4B). In four tumors, the cells were almost devoid of cyto-
plasm with round nuclei (Figure 1: A2-4 and A6, and, Fig-
ure 4E, 4F, 4I, 4J, 4M and 4N). In these tumors, anucleated
areas could be seen. They were not always centred on a
vessel, imparting an initial impression of a neuroid-
derived tumor. In one of these tumors, transition between
neuroid to clear cell pattern was observed (Figure 1: A4
and Figure 4I and 4J). Finally, the remaining two tumors
were composed of intermediate-to-large, ovoid or fusi-
form cells, with abundant cytoplasm that appeared palely
stained or eosinophilic, suggestive of an oligo-astrocytic
tumor (Figure 1: A7-8 and Figure 4Q and 4R).
The immuno-histochemical profile was similar in all tri-
somy 19 ependymomas. GFAP was always detected,
although with intra and inter-tumoral variations. Some
tumoral areas could be almost completely negative (Fig-
ure 3E), while others showed intensely labeled ependy-
mal cells (Figure 3D, 4D, 4H, 4P and 4T). At least,
perivascular positivity of cell end-feet was always found.
EMA immunopositivity, appearing as intracytoplasmic
dots, was observed focally in all tumors (Figure 3F, 4C,
4G, 4K, 4O and 4S). Immunolabeling for neurofilaments
(Figure 3H) and NeuN (Figure 3I) was consistently nega-
tive in the tumor, although it was positive in the sur-
rounding normal brain.Molecular Cancer 2007, 6:47 http://www.molecular-cancer.com/content/6/1/47
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A) Array-CGH ideograms of the most frequently observed chromosomal anomalies in trisomy 19 ependymomas Figure 2
A) Array-CGH ideograms of the most frequently observed chromosomal anomalies in trisomy 19 ependymomas. Blue dots: 
ratio between tumor DNA and control DNA; red dots: ratio between control DNA and tumor DNA. Ratio of 1 indicates nor-
mal DNA content (presence of two alleles, chromosome 2: A6). Separation of the lines corresponds to gain of tumoral DNA 
(blue dots going up, chromosome 19: A1, A2 and A9 and, chromosome 11: A4) or loss of tumoral DNA (blue dots going 
down, chromosome 13: A6 and, chromosome 9: A4). B) Scheme of array-CGH results of trisomy 19 ependymomas. Alto-
gether 118 genetic anomalies detected, mean: 13 per tumor, consisting of 74 gains (64%) and 44 losses (36%). Numbers corre-
spond to tumors. C) Genetic alterations presented at least in 66% (6/9) of trisomy 19 ependymomas (A1-A9) compared to 
two controls (Ep.: B1 and B19). Trisomy 19 observed in all cases, although in one tumor (A4) the telomeric long arm was not 
amplified. Deletion of 13q21.31-31.2 and deletions on chromosme 9 (M: monosomy; M: monosomy without 9qter loss; 9p: 9p 
deletion and Int: intertitial p and q deletions) were found in 7/9 tumors (78%). Amplification of 11q13.3-13.4 was detected in 6/
9 (66%) of the tumors.Molecular Cancer 2007, 6:47 http://www.molecular-cancer.com/content/6/1/47
Page 5 of 10
(page number not for citation purposes)
All but one ependymal tumor with trisomy 19 presented
at least two of the following signs of anaplasia: (1)
endothelial cell proliferation, (2) Ki-67 labeling index
higher than 10% and (3) frequent mitotic figures (Figure
1). Therefore, they were considered as WHO grade III
tumors.
Discussion
We recognized a new genetico-histological association
within ependymal tumors, the trisomy 19 ependymoma.
Most of these tumors are supra-tentorial WHO grade III
tumors of the young. Trisomy of chromosome 19 is fre-
quently associated with deletion of 13q21.31-31.2, three
copies of 11q13.3-13.4, and/or deletions on chromosome
9. The histological hallmark is a prominent branched cap-
illary network around which tumoral cells are regularly
dispersed. Clear cells may be present in these compact
lesions, evoking the diagnosis of clear cell ependymoma.
Trisomy 19 ependymomas have an immunohistological
profile of ependymal tumors: positive for glial fibrillary
acidic protein (GFAP) and epithelial membrane antigen
(EMA), and negative for neuronal markers.
In the "cancer chromosomes database" [12], we calcu-
lated chromosomal trisomy to occur with a mean fre-
quency of 4% among all tumors (n = 50,380), which was
Three phenotypic variants of trisomy 19 ependymomas Figure 4
Three phenotypic variants of trisomy 19 ependymomas. 
Clear cells, indicative of clear cell ependymoma, a subgroup 
of trisomy 19 ependymoma (HE: A, 250× and B, 60×); PNET-
like appearance, because tumoral cells almost devoid of cyto-
plasm, presence of rounded nuclei and nuclei-free regions 
not always centered on vessels (HE: E, 190×; F, 60×; I, 375×; 
J, 90×; M, 130× and N, 30×); and oligo-astrocytoma appear-
ance, due to large eosinophilic tumoral cells and presence of 
chicken-wire vessels (HE: Q, 125× and R, 60×). Ependymal 
nature confirmed by GFAP positivity of end-feets (D, 125×; 
H, 60×; L, 160×; P, 375× and T, 375×) and intra-cytoplasmic 
EMA dots (C, 160×; G,160×; K, 250×, O, 250× and S, 500×). 
Pictures A, B, C and D correspond to tumor A1; pictures E, 
F, G and H to tumor A2; pictures I, J, K and L to tumor A4; 
pictures M, N, O and P to tumor A3, pictures Q, R, S and T 
to tumor A8.
Histological characteristics of trisomy 19 ependymoma: com- pactness with clear cut border (A, HE, 30×); rich branched  capillary network (B, HE, 90×); perivascular pseudorosettes,  always observed, but can be rare (C, HE, 250×); GFAP posi- tivity, always observed (D, GFAP, 125×) but can be focal with  large GFAP negative area (E, GFAP, 125×); focal region of  tumoral cells with intra-cytoplasmic EMA dots, always found  (F, EMA, 310×); Ki67 >10% (G, Ki67, 60×); neuronal mark- ers: negative in the tumor, positive in the surrounding brain  parenchyma (H: NF, 30× and I: Neu-N, 30×) Figure 3
Histological characteristics of trisomy 19 ependymoma: com-
pactness with clear cut border (A, HE, 30×); rich branched 
capillary network (B, HE, 90×); perivascular pseudorosettes, 
always observed, but can be rare (C, HE, 250×); GFAP posi-
tivity, always observed (D, GFAP, 125×) but can be focal with 
large GFAP negative area (E, GFAP, 125×); focal region of 
tumoral cells with intra-cytoplasmic EMA dots, always found 
(F, EMA, 310×); Ki67 >10% (G, Ki67, 60×); neuronal mark-
ers: negative in the tumor, positive in the surrounding brain 
parenchyma (H: NF, 30× and I: Neu-N, 30×).Molecular Cancer 2007, 6:47 http://www.molecular-cancer.com/content/6/1/47
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comparable for chromosome 19 (4.2%). In brain tumors
(n = 1644), trisomy 19 occurred in 6%, but only in about
3% of meningiomas (n = 817) and, interestingly in about
9% of astrocytomas (n = 569) and ependymomas (n =
111). This more frequent observation in glial tumors sug-
gests an ethiopathogenic role within this group of tumors.
Our results linked trisomy 19 to a subset of supra-tentorial
ependymomas that we could recognise on histological cri-
teria. Furthermore, in the two control series, we observed
only one tumor with a partial chromosome 19 trisomy
(3,8%), giving a p value < 0,001 for the presence of tri-
somy 19 in our tumor group of interest. Because trisomy
19 appears non-complete in some of our ependymomas,
it has to be looked for using a technique which profiles
the entire chromosome 19 for copy number alterations.
The other copy changes are helpful in recognition of tri-
somy 19 ependymomas. Interstitial deletion of 13q and
deletions on chromosome 9 were identified in 7/9 (78%)
of the tumors. They were observed associated with tri-
somy 19 only once and twice respectively in the NCBI
database (frequency of 0,9% and 1,8%) [12], and not in
our control. Similarly, association between trisomy 19
and amplification of 11q13.3-13.4, which was observed
in 6/9 (66%) of our trisomy 19 ependymomas, was rarely
reported in the NCBI database (4,5%) and not found in
the control series. All of our trisomy 19 ependymomas
presented at least one of these associated anomalies
(100%) and 7/9 (78%) two of them.
The WHO classification describes clear cell ependymomas
as having an "oligodendroglia-like appearance with clear
perinuclear haloes" [1]. This definition highlights the
importance of two histological features: clear cells and
chicken-wire vessels. The combination of our genetic and
histological data emphasized the latter. Chicken-wire ves-
sels were constantly observed in ependymal tumors bear-
ing trisomy 19, whereas clear cells were not. Thus clear cell
ependymoma are a subgroup of trisomy 19 ependymoma.
Previously, trisomy 19 ependymomas may have been
reported as haemangioblastoma, PNET, central neurocy-
toma, oligodendroglioma or oligo-astrocytoma [13-16].
Amongst them, haemangioblastoma is the only one with
a reticulin rich stroma. Neuronal markers are positive in
PNET and central neurocytoma, but negative in trisomy
19 ependymoma. GFAP and EMA, which are negative in
neuronal tumors, are positive in ependymal tumors,
although this can be focal [14,17]. Because of this, differ-
ential diagnosis between trisomy 19 ependymomas and
oligodendroglioma/oligoastrocytoma may be difficult.
Genetic analysis can help. Deletion of 1p and 19q is
restricted to oligodendroglioma and oligo-astrocytoma
[18,19], whereas trisomy 19 suggests trisomy 19 ependy-
moma.
Rickert and co-workers recently analyzed by classical CGH
a series of 13 clear cell ependymomas [20]. They pin-
pointed monosomy 9 to be always associated with WHO
grade III and sometimes with WHO grade II clear cell
ependymoma. They defined clear cell ependymomas as
comprising of at least 50% of clear cells. In our series of
trisomy 19 ependymomas, 3/9 tumors contained similar
percentage of clear cells (Figure 1: A1, A5 and A9), one less
(Figure 1: A4), and five none (Figure 1: A2-3, A6-8). All 4
trisomy 19 ependymomas with clear cells had an addi-
tional chromosome 9 deletion, in agreement with the
published series. Amongst the 5 trisomy 19 ependymo-
mas devoid of clear cells, three had a deletion on chromo-
some 9. Moreover, chromosome 9 deletion was also
observed in other subtypes of ependymomas (Figure 1:
B1-4). There is a technical difference as well. The total
number of reported chromosomal anomalies was 2,7 per
tumor in the Rickert analysis, whereas we demonstrated a
mean of 13 anomalies per tumor, illustrating the higher
resolution of array-CGH. In addition, Rickert's series did
not demonstrate anomalies of chromosome 19, whereas
trisomies of this chromosome were observed in a series of
clear cell ependymomas analyzed by FISH [21]. Presence
of high amount of heterochromatin in chromosome 19 is
known to induce false positive and negative CGH results,
a reason why this chromosome is often difficult to inter-
pret and frequently excluded from classical CGH analysis
[22,23].
Cancer arises from accumulations of genetic changes in
pathways involved in cell cycle, cell proliferation, apopto-
sis, angiogenesis and interaction with extracellular matrix
[24]. Interestingly, all these biological processes can
already be altered by genes located on chromosome 19
(Figure 5) [25-41]. The 3 other chromosomic regions
involved in trisomy 19 ependymomas could reinforce
potential deregulation of these pathways (Figure 5) [35-
44]. Furthermore, epigenetic changes are of importance.
Chromosome 19 contains BRG1 (19p13.2), and chromo-
some 9 BRM (9p24.3). These genes are ATPase subunits of
SWI/SNF complex, one of the two enzymes implicated in
chromatine remodeling and promotor methylation [45].
Conclusion
We describe a new subgroup of ependymal tumors, the tri-
somy 19 ependymoma, which bears specific clinico-histo-
logical characteristics. This newly identified association is
a significant additional argument for considering dispar-
ity in tumorigenesis pathways involved in ependymal
tumors as suggested by Lukashova and co-authors [46].
Differences have also been illustrated on differential
expression of DAL-1 and NF2 between intracranial and
spinal cord ependymomas [47], methylation of RASSF1A
and TRAIL pathway-related genes in childhood intracra-
nial ependymomas [48], and methylation of 9p21 tumorMolecular Cancer 2007, 6:47 http://www.molecular-cancer.com/content/6/1/47
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suppressor genes following clinico-histological parame-
ters of ependymal tumors [7]. Further genetico-histologi-
cal dissection of tumors is needed for development of
targeted oncological practice.
Methods
Tumor samples and DNA extraction
Two independent series of ependymal tumors were ana-
lyzed. None of the tumors were simultaneously included
in both series. The first one comprised of 24 frozen epend-
ymal tumors and the second of 149 formalin-fixed and
paraffin-embedded ones. Both series were retrieved from
the archives of 9 neuropathological centers based on their
original diagnosis of ependymomas (Institute of Neurol-
ogy, London, UK; Hospital Roger Salingro, Lille, France;
Laboratory of neuropathology, CHU-Caen, France; St. Luc
hospital, Université catholique de Louvain, Belgium; La
Timone's Hospital, AP-HM tumor bank, Marseille, France;
Hospital Erasme, Université libre de Bruxelles, Belgium;
CHU Kremlin-Bicêtre, Paris, France; CHU-Lariboisière,
Paris, France; University of Newcastle, Newcastle, UK).
Before inclusion in the study, all tumor diagnoses were
revised following the latest WHO classification [1]. The
study was approved by the ethics committee of the Medi-
cal Faculty of Université catholique de Louvain, Brussels,
Belgium.
The 24 frozen ependymomas were obtained from 23
patients, 18 corresponding to primary tumors and 6 to
recurrent tumors. For one patient, we received both the
primary and the recurrent tumor. Age at operation varied
between 4 months and 63 years with a mean age of 27.5
years and a mediane age of 33 years. Histologically, the
tumors were classified as myxopapillary ependymomas
(WHO grade I, n = 2, 8%), ependymomas (WHO grade II,
n = 11, 46%) and anaplastic ependymomas (WHO grade
III, n = 11, 46%). Thirteen were located in the spinal cord
(54%), 4 in the posterior fossa (17%) and 7 in the
supratentorial compartment (29%). This series was used
for single nucleotide polymorphism (SNP) microarrays
analyses.
The 149 formalin-fixed and paraffin-embedded tumors
were obtained from 146 patients. In three patients,
tumors were collected from 2 consecutive surgical resec-
tions. In 17 patients samples were available only from the
recurrence. Age at operation varied from 3 months to 80.6
years, with a mean of 29.4 years and a median of 27.4
years. More precisely, 19 patients were aged between 0
and 3 years (13%), 29 between 3 and 15 years (19%), and
100 were older than 15 years (67%). For 1 patient, the age
was unknown (<1%). Histologically, the tumors were
classified as subependymomas (WHO grade I, n = 15,
10%), myxopapillary ependymomas (WHO grade I, n =
28, 19%), ependymomas (WHO grade II, n = 63, 42%),
and anaplastic ependymomas (WHO grade III, n = 43,
29%). Forty-nine were located in the spinal cord (32.9%),
63 in the posterior fossa (42.3%), 33 in the supra-tento-
rial compartment (22.1%), and 4 in an unknown location
(2.7%) This series was used for microsatellite analysis and
array-CGH.
For microsatellite analysis, DNA was extracted from for-
malin-fixed and paraffin-embedded tumors using
QIAamp DNA Mini Kit (Qiagen, Westburg, Leusden, Hol-
land) after deparaffinization of tumor shaves with xylene.
This was performed following a tissue dissection step if
section contained more than 10% of normal brain paren-
chyma. For 6 patients, enough normal tissue was obtained
to be used as control DNA.
For array-CGH, tumoral DNA was extracted from forma-
lin fixed and paraffin embedded tumors using PURE-
GENE DNA Purification Kit (Gentra Systems,
Minneapolis, Minnesota, USA) after deparaffinization of
tumoral shaves using xylene. Control DNAs were
extracted from blood samples of healthy individuals.
Pools of either 5 males or 5 females were constituted.
Absence of DNA anomaly in both pools was confirmed by
hybridization of male pool against female pool. For SNP
chip analysis, DNA was extracted from frozen tumors as
described for array-CGH, but without deparaffinization.
Immunohistochemistry
Immunohistochemistry was performed following classi-
cal protocols. Briefly, 5 µm sections were deparaffinized
Scheme of pathways involved in trisomy 19 ependymoma Figure 5
Scheme of pathways involved in trisomy 19 ependymoma. 
Cancer occurs because of accumulation of defects implying 
cell cycle, cell proliferation, differentiation, apoptosis, cell 
interaction with surrounding stroma and angiogenesis. All 
these pathways could be deregulated when considering genes 
located in the 4 chromosomic regions most frequently 
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using Histosafe (Yvsolab, Beerse, Belgium), rehydrated in
propanol and finally water. After blocking endogenous
peroxydase by incubating sections for 30 min in 0.3%
H2O2, antigens were retrieved using a citrate buffer pH 5.7
at 95°C for 95 min. Non-specific binding was inhibited
under 10% normal goat serum and 1% bovine serum
albumin. The slides were subsequently incubated over-
night at 4°C with the following primary antibodies: Glial
Fibrillary Acidic Protein (GFAP, rabbit polyclonal
obtained from Dako, dilution 1/2000), Epithelial Mem-
brane Antigen (EMA, mouse monoclonal, Neomarkers,
dilution 1/200), Neurofilaments 68 and 200 (NF, mouse
monoclonal, Sigma and Boehringer, used mixed together
at 1/200 and 1/25 dilution), Neuron-specific Nuclear Pro-
tein (NeuN, mouse monoclonal, Chemicon, dilution 1/
100), and Ki-67 (mouse monoclonal, Dako, dilution 1/
100). After a wash with Tris-HCl 0.05 M, pH 7.4, either a
biotinylated anti-mouse (Vector, dilution 1/500) or anti-
rabbit (Boerhinger, dilution 1/500) secondary antibody
was applied on the sections for 30 min at room tempera-
ture. The slides were then washed with Tris-buffer and
incubated with a streptavidin-peroxydase complex
(Roche, dilution 1/100) for 30 min at room temperature.
After a wash, the chromogen was revealed using 0.05%
DAB (Fluka) in PBS buffer (pH 7.2) with 0,01% H2O2 dur-
ing 10 min. The slides were rinsed with water, counter-
stained with Mayer's Hematoxylin and mounted.
Microsatellite analysis
Twenty-nine microsatellites of chromosome 9 were cho-
sen from the Human MapPairsTM Genome-Wide Screen-
ing Set 8 (Weber set, Research Genetics) or 9 (Li-Cor,
Westburg, the Netherlands), or in the Unified Database
for Human Genome Mapping on the basis of their map
position [49]. The latter were synthesized by Eurogentec
(Belgium) or MWG (Germany). Of the 29 microsatellites,
23 were located on 9p (D9S917, D9S288, D9S1810,
D9S2169, D9S2156, located at 9p24; D9S775, D9S921,
D9S168, D9S269, D9S254, located at 9p23; D9S285,
D9S156, D9S157, D9S925, located at 9p22; D9S162,
D9S1749, D9S1748, D9S171, D9S1679, D9S1121,
D9S251, D9S1118, and D9S1788, located at 9p21) and 6
were located on 9q (D9S301, D9S1122, D9S922, located
at 9q21; D9S930, located at 9q32; D9S934, and
D9S1825, located at 9q33).
For amplification of microsatellites with primers of the
Weber set 8, one of the two primers was end-labeled with
gamma-32P ATP (Amersham-Pharmacia), using T4 poly-
nucleotide kinase (TAKARA). PCRs were performed in a
final volume of 10 µl containing 18 ng of template DNA,
0.6 µM of each primer, 1× Biotools buffer, 0.2 mM of each
dNTP, and 0.025 U/µL Biotools DNA polymerase (Lab
Systems, Belgium). After 5-minutes denaturation at 95°C,
35 cycles were realized with 94°C for 40 seconds, 55°C
for 50 seconds and 72°C for 50 seconds, with a final
extension of 5 minutes at 72°C. For amplification of the
Weber set 9 (Westburg, Holland) and other fluorescent
markers modified with IRD 700 or IRD 800 fluoro-
chromes (MWG, Germany), PCRs were carried out as
above, except that 36 ng of template DNA and 2 to 5 mM
MgCl2 were used. All PCRs were performed in duplicate.
To visualize alleles of microsatellites, amplicons were heat
denatured (95°C for 5 minutes) after addition of 10 µl of
a denaturing loading buffer. 2.5 µl of the obtained solu-
tion was run on gel. For radio-active markers, a 5% poly-
acrylamide denaturing gel was used. The gels were
subsequently vacuum-dried and exposed overnight on
Kodak X-OMAT AR films (Amersham-Pharmacia, Bel-
gium). For fluorescent markers, a 6,5% SequaGel XR gel
(National Diagnostics) was used on a Li-Cor Gene Readir
4200 DNA Analyzer (Westburg, the Netherlands), oper-
ated by E-Seq DNA Sequencing and Analysis software
(version 1.0 Westburg, the Netherlands). The analysis was
made with Gene ImagIR software (version 4.0, Westburg,
the Netherlands).
Interpretation of microsatellite results was performed as
previously described [50]. Briefly, the status of chromo-
some 9, for a given tumor, was only taken into account
when more than 70% of the tested microsatellites gave
interpretable amplicons. In addition, to be considered
monosomic, 90% of the amplicons had to reveal either
the presence of a single allele or an important difference
in intensity between the two alleles.
Array-CGH
Array-CGH was performed according to manufacturer's
instructions (Spectral Genomics, USA) with few modifica-
tions. After DNA extraction and purification with the Qia-
gen PCR purification kit (Westburg, Holland), the DNAs
were labeled with Cy3-dCTP and Cy5-dCTP (Amersham)
using the Gibco/BRL Bioprime DNA labeling kit. Labeled
test and reference DNA were subsequently mixed in the
proportion of 1.2–1.4 µg of Cy3 labeled DNA to 1 µg of
Cy5 labeled DNA. Spectral Hybridization buffer I contain-
ing cot-1 DNA was added to the mixture. DNAs were pre-
cipitated with 5 M NaCl/isopropanol solution, rinsed
with 70% ethanol and air-dried. The precipitate was resus-
pended in water and mixed with the Spectral Hybridiza-
tion buffer II. Denaturation at 72°C for 10 minutes was
followed by incubation of 10 min on ice and subse-
quently of 30 min at 37°C. Hybridization on the array
(HU 1K BAC Array, Spectral Genomics, USA) was per-
formed in a hybridization chamber at 37°C for 16 hours.
To increase specificity, each hybridization was also per-
formed by flipping tumor and control fluorochromes. The
arrays were rinsed in the 5 subsequent solutions: 2 × SSC,
0.5% SDS for 20 min at 45°C; 2 × SSC, 50% formamideMolecular Cancer 2007, 6:47 http://www.molecular-cancer.com/content/6/1/47
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for 20 min at 45°C; 2 × SSC, 0.1 × NP-40 for 20 min at
45°C, 0.2 × SSC for 10 min at 45°C, and a brief rinse in
H2O. The arrays were scanned and analyzed using the
Spectralware software (version 2,0).
Single Nucleotide Polymorphism microarrays
The Affymetrix high-density (50 K) oligonucleotide array-
based SNP genotyping was performed according to the
standard protocol for Affymetrix GeneChip Mapping 100
K arrays (Affymetrix, Inc.). Only tumors with a call rate
higher than 94% were included in the analysis. Briefly,
250 ng of genomic DNA was digested by a restriction
enzyme (XbaI), which allowed to ligate an adaptor used
for PCR primer annealing for the subsequent whole
genome amplification. The obtained PCR products were
size-restricted by digesting with DNAseI. This fragmented
DNA was labeled with a biotinylated nucleotide analogue
and hybridised to the microarray. Hybridised fragments
of tumoral DNA were revealed using a three step detection
system constituted of a first streptavidin-phycoerythrin
binding, followed by an anti-streptavidin biotinylated
antibody incubation and, lastly, a final streptavidin-phy-
coerythrin step. After scanning of the array, the SNPs were
genotyped by GeneChip DNA Analysis Software (GDAS,
version 3.0.2.8; Affymetrix, Inc.). Raw signals (genotype
and intensity data of the SNP probes) were exported from
the Affymetrix platform and analyzed for copy number
alterations using the Copy Number Analyser for Gene-
Chip (CNAG, version 1.0) [51] and dCHIP (version 2005)
[52] softwares.
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